- Home
- QH vs BOLD Comparison
QH vs BOLD Comparison
Compare QH & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QH | BOLD |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6M | 26.2M |
| IPO Year | 2020 | 2024 |
Fundamental Metrics
Financial Performance| Metric | QH | BOLD |
|---|---|---|
| Price | $1.15 | $1.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 828.8K | 218.0K |
| Earning Date | 09-26-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $357,118,848.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.37 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.74 | $1.00 |
| 52 Week High | $169.07 | $3.12 |
Technical Indicators
Market Signals| Indicator | QH | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 40.75 | 56.30 |
| Support Level | $1.23 | $1.11 |
| Resistance Level | $2.20 | $1.37 |
| Average True Range (ATR) | 0.25 | 0.08 |
| MACD | 0.12 | 0.02 |
| Stochastic Oscillator | 11.24 | 57.81 |
Price Performance
Historical ComparisonAbout QH Quhuo Limited American Depository Shares
Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.